Biovail profit dips but hunt for deals continues

with Swiss biotech Santhera over a drug to treat dyskinesia, or abnormality in performing voluntary muscle movements, in Parkinson's disease. "They've been aggressive over the last 18 months and I think they have established a track record and I think...